

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 August 2021 (12.08.2021)



(10) International Publication Number
WO 2021/158523 A1

- (51) **International Patent Classification:**
C07K 14/705 (2006.01) *C07K 16/44* (2006.01)
- (21) **International Application Number:**
PCT/US2021/016177
- (22) **International Filing Date:**
02 February 2021 (02.02.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/969,931 04 February 2020 (04.02.2020) US
- (71) **Applicant:** SEATTLE CHILDREN'S HOSPITAL
(DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) [US/US]; 1900 Ninth Avenue, Seattle, Washington 98101 (US).
- (72) **Inventors:** JENSEN, Michael C.; c/o Seattle Children's Hospital (dba Seattle Children's Research Institute), 1900 Ninth Avenue, Seattle, Washington 98101 (US). MATTHAEI, James F.; c/o Seattle Children's Hospital (dba Seattle Children's Research Institute), 1900 Ninth Avenue, Seattle, Washington 98101 (US). CHENG, Joseph K.; c/o Seattle Children's Hospital (dba Seattle Children's Research Institute), 1900 Ninth Avenue, Seattle, Washington 98101 (US).
- (74) **Agent:** FURMAN, PH.D., Eric S.; Knobbe Martens Olson & Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, California 92614 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** ANTI-DINITROPHENOL CHIMERIC ANTIGEN RECEPTORS




FIG. 4

(57) **Abstract:** Embodiments provided herein include methods and compositions comprising anti-dinitrophenol chimeric antigen receptors (CARs). Some embodiments include nucleic acids encoding such CARs, polypeptides encoded by such nucleic acids, cells comprising such nucleic acids or polypeptides, and methods utilizing such cells. Some embodiments also include the use of dinitrophenol (DNP) and derivatives thereof.

WO 2021/158523 A1